Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles J Link

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Cancer Immunology, Immunotherapy : CII|April 14, 2006
Co-expression of alpha(1,3)galactosyltransferase and Bacillus thuringiensis PIPLC enhances hyperacute rejection of tumor cellsDaniel J Hellrung, Serguei Kisselev, Charles J Link
Methods in Molecular Medicine|January 16, 2003
Herpes simplex amplicon vectorsCharles J Link, Nicholas N Vahanian, Suming Wang
Human Gene Therapy|December 13, 2003
Effective suppression of class I major histocompatibility complex expression by the US11 or ICP47 genes can be limited by cell type or interferon-gamma exposureThomas J Radosevich, Tatiana Seregina, Charles J Link
Cancer Research|March 5, 2003
Immunity to the alpha(1,3)galactosyl epitope provides protection in mice challenged with colon cancer cells expressing alpha(1,3)galactosyl-transferase: a novel suicide gene for cancer gene therapyRobert C Unfer, Daniel Hellrung, Charles J Link
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|September 26, 2006
High-throughput fluorescent screening of transgenic animals: phenotyping and haplotypingDaniel J Hellrung, Gabriela Rossi, Charles J Link
Cancer Gene Therapy|March 28, 2002
Antitumor effects on human melanoma xenografts of an amplicon vector transducing the herpes thymidine kinase gene followed by ganciclovirSuming Wang, Jianguo Qi, Michael Smith, et al.
The Journal of Gene Medicine|January 11, 2013
U6 promoter-enhanced GlnUAG suppressor tRNA has higher suppression efficacy and can be stably expressed in 293 cellsRamesh Koukuntla, William J Ramsey, Won-Bin Young, et al.
Cancer Immunology, Immunotherapy : CII|May 13, 2005
Complete protection against melanoma in absence of autoimmune depigmentation after rejection of melanoma cells expressing alpha(1,3)galactosyl epitopesGabriela R Rossi, Robert C Unfer, Tatiana Seregina, et al.
Medical Hypotheses|February 8, 2005
Pharmacological manipulation of ataxia-telangiectasia kinase activity as a treatment for Parkinson's diseaseRodney Edwin Shackelford, Ryan P Manuszak, Steven C Heard, et al.
DNA Repair|September 1, 2004
Iron chelators increase the resistance of Ataxia telangeictasia cells to oxidative stressRodney E Shackelford, Ryan P Manuszak, Cybele D Johnson, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Cancer Immunology, Immunotherapy : CII|April 14, 2006
Co-expression of alpha(1,3)galactosyltransferase and Bacillus thuringiensis PIPLC enhances hyperacute rejection of tumor cellsDaniel J Hellrung, Serguei Kisselev, Charles J Link
Methods in Molecular Medicine|January 16, 2003
Herpes simplex amplicon vectorsCharles J Link, Nicholas N Vahanian, Suming Wang
Human Gene Therapy|December 13, 2003
Effective suppression of class I major histocompatibility complex expression by the US11 or ICP47 genes can be limited by cell type or interferon-gamma exposureThomas J Radosevich, Tatiana Seregina, Charles J Link
Cancer Research|March 5, 2003
Immunity to the alpha(1,3)galactosyl epitope provides protection in mice challenged with colon cancer cells expressing alpha(1,3)galactosyl-transferase: a novel suicide gene for cancer gene therapyRobert C Unfer, Daniel Hellrung, Charles J Link
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|September 26, 2006
High-throughput fluorescent screening of transgenic animals: phenotyping and haplotypingDaniel J Hellrung, Gabriela Rossi, Charles J Link
Cancer Gene Therapy|March 28, 2002
Antitumor effects on human melanoma xenografts of an amplicon vector transducing the herpes thymidine kinase gene followed by ganciclovirSuming Wang, Jianguo Qi, Michael Smith, et al.
The Journal of Gene Medicine|January 11, 2013
U6 promoter-enhanced GlnUAG suppressor tRNA has higher suppression efficacy and can be stably expressed in 293 cellsRamesh Koukuntla, William J Ramsey, Won-Bin Young, et al.
Cancer Immunology, Immunotherapy : CII|May 13, 2005
Complete protection against melanoma in absence of autoimmune depigmentation after rejection of melanoma cells expressing alpha(1,3)galactosyl epitopesGabriela R Rossi, Robert C Unfer, Tatiana Seregina, et al.
Medical Hypotheses|February 8, 2005
Pharmacological manipulation of ataxia-telangiectasia kinase activity as a treatment for Parkinson's diseaseRodney Edwin Shackelford, Ryan P Manuszak, Steven C Heard, et al.
DNA Repair|September 1, 2004
Iron chelators increase the resistance of Ataxia telangeictasia cells to oxidative stressRodney E Shackelford, Ryan P Manuszak, Cybele D Johnson, et al.
Pageof 3